Association of *Helicobacter pylori babA2* with peptic ulcer disease and gastric cancer

Mo-Ye Chen, Cai-Yun He, Xue Meng, Yuan Yuan

Mo-Ye Chen, Cai-Yun He, Xue Meng, Yuan Yuan, Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

Mo-Ye Chen, Cai-Yun He, Xue Meng, Yuan Yuan, Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Department, Shenyang 110001, Liaoning Province, China

**Author contributions:** Chen MY and He CY contributed equally to this work; Chen MY and He CY designed the study and performed the data analysis as joint first authors; Chen MY, He CY and Meng X contributed to the discussion and drafted the manuscript; Yuan Y designed the study, contributed to the discussion and edited the manuscript as corresponding author; all authors critically reviewed the manuscript and gave final approval of the version to be published.

**Supported by** Grants from National Basic Research Program of China, 973 Program Ref No. 2010CB529304; the Grants of the Science and Technology Project of Liaoning province, Ref No. 2011225002; and the Grants of the Science Project of Liaoning Province, Ref [2008]621

**Correspondence to:** Yuan Yuan, Professor, Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang 110001, Liaoning Province, China. yyuan@mail.cmu.edu.cn

**Telephone:** +86-24-83282153  **Fax:** +86-24-83282292

Received: January 18, 2013  Revised: April 3, 2013

Accepted: May 16, 2013  Published online: July 14, 2013

**Abstract**

**AIM:** To investigate the association between *babA2* gene and peptic ulcer disease (PUD) and gastric cancer (GC) in *Helicobacter pylori*-infected populations.

**METHODS:** We evaluated the relationship between *babA2* and clinical outcomes (PUD and GC) using a meta-analysis. A literature search was performed using the PubMed and Web of Science databases for relevant case-control studies that met the defined inclusion criteria. The ORs and 95% CIs were calculated to estimate the association between *babA2* genotype and clinical outcomes. A fixed-effect or random-effect model was performed depending on the absence or presence of significant heterogeneity.

**RESULTS:** A total of 25 articles with 38 studies met the inclusion criteria and were finally included in this meta-analysis. The results showed that the *babA2* genotype was significantly associated with an increased risk of PUD (OR = 2.069, 95% CI: 1.530-2.794, *P* < 0.001) and especially in the subgroup of duodenal ulcer (OR = 1.588, 95% CI: 1.141-2.209, *P* = 0.006). Moreover, a significant association between *babA2* gene and PUD and duodenal ulcer (OR = 2.739, 95% CI: 1.860-4.032, *P* < 0.001; OR = 2.239, 95% CI: 1.468-3.415, *P* < 0.001, respectively) was observed in western countries but not in Asian countries.

**CONCLUSION:** We demonstrated that the presence of *babA2* may be associated with increased risks for PUD, especially duodenal ulcer, in western countries.

© 2013 Baishideng. All rights reserved.

**Key words:** *Helicobacter pylori*; *babA2*; Peptic ulcer; Gastric cancer; Risk

**Core tip:** BabA encoded by *babA2* gene is an outer membrane protein of *Helicobacter pylori* (*H. pylori*), which plays a key role in facilitating bacterial colonization in the stomach. The association between *babA2* and *H. pylori*-related gastroduodenal diseases is still controversial. We summarized a total of 25 case-control articles with 38 studies in this meta-analysis and evaluated the relationship between *babA2* and clinical outcomes. The presence of *babA2* may contribute to increased risk of peptic ulcer disease (PUD), especially duodenal ulcer, in western countries. In Asians, *babA2* genotype only showed a marginal association with PUD risk, which requires further investigation.
INTRODUCTION

*Helicobacter pylori* (H. pylori) is a Gram-negative spiral bacterium that may colonize the human gastric mucosa and establish a life-long infection.[1] Although *H. pylori* infects approximately half of the population worldwide, especially in developing countries, the majority of infected people remain asymptomatic. Only 15%-20% of those infected develop severe gastroduodenal diseases, such as peptic ulcer disease (PUD), gastric cancer (GC), and mucosa-associated lymphoid tissue lymphoma.[2-4] In addition to the host and environmental factors, another important reason for the diverse clinical outcomes is the differences in virulence factors among *H. pylori* strains.[5] For example, *H. pylori* strains harboring the vacuolating toxin A (*vacA*) and the cytotoxic-associated antigen (*cagA*) have been proposed as possible risk factors for PUD and GC.[6,7]

Successful colonization in the stomach is the most important step for the pathogenicity of *H. pylori* infection. It is generally accepted that bacterial attachment to the gastric epithelium is the first critical stage of colonization by *H. pylori*.[8] The blood group antigen binding adhesin (BabA) is a well-described outer membrane protein of *H. pylori* that targets fucoylated Lewis blood group antigens presented on gastric epithelium.[9,10] Three *babA* allelic types have been identified, including *babA1*, *babA2* and *babB*; however, only the product of the *babA2* gene is necessary for enduring the bacteria with Lewis' binding activity.[9] In 1999, Gerhard et al.[9] first reported a positive association between a *babA2*-gene-positive strain and duodenal ulcer (DU) and GC. Subsequently, a series of studies of the association between *babA2* gene and PUD and GC have been done, but with inconsistent or conflicting conclusions.[9,11]

We proposed a hypothesis that bacterial adherence factor BabA mediating close attachment to the epithelium may contribute to pathogenesis of PUD and/or GC. So far, it has not been possible to draw any causal conclusion about the relationship between the *babA2* gene and specific diseases, partly because of the small size of individual studies. Therefore, in the present study, we conducted a meta-analysis, combining available data from published case-control studies, to obtain a more precise estimate of the association between *babA2* gene and PUD and GC in *H. pylori*-infected populations.

MATERIALS AND METHODS

**Literature search strategy**

A literature search was performed using the PubMed and Web of Science databases for articles estimating the association between *babA2* gene and clinical outcomes in *H. pylori*-infected populations. All enrolled studies were published from January 1997 to October 2012 and retrieved using one of the keywords “*babA2*” or “*babA2*” in combination with “*Helicobacter pylori*”. The search was performed without restriction on language.

**Inclusion criteria**

The criteria used to select studies for this meta-analysis were as follows: (1) fully published case-control studies [case group included DU, gastric ulcer (GU), PUD or GC, and the control group included gastritis or nonulcer disease (NUD)]; (2) studies described the relationship between *babA2* gene status and clinical outcomes; (3) the presence of *babA2* was examined by polymerase chain reaction (PCR); and (4) the papers were written in English.

**Exclusion criteria**

The exclusion criteria were as follows: (1) the results came from review articles; (2) there was no integrated raw data; (3) *in vitro* studies or animal experiments; (4) studies with abstract only; and (5) studies with children.

**Data extraction**

Evaluation of all potentially relevant articles and extraction of raw data were independently performed by two investigators (Chen MY and He CY). Disagreements were resolved through discussion. We collected information on the following items from each study: first author's name, year of publication, countries and areas of the study population, *babA2* status and clinical outcomes (DU, GU, PUD and GC), and the total number of cases and controls.

**Statistical analysis**

All statistical analyses were performed using STATA version 11.0 (College Station, TX, United States). Two-sided *P* values were evaluated in this meta-analysis and *P* < 0.05 was considered statistically significant. The strength of the association between the *babA2* gene and clinical outcomes was estimated by OR and corresponding 95% CIs. The statistical heterogeneity among the included studies was assessed by *χ*²-based *I*² and *Q* tests. If the heterogeneity was considered not significant (with *P* > 0.1 for *Q* test) among studies, a fixed-effects model based on the Mantel-Haenszel method[12] was used to calculate the pooled OR. On the contrary, a random-effects model based on the DerSimonian and Laird method[13] was used to assess the pooled OR when the *P* value of the *Q* test was < 0.1. In addition, a sensitivity analysis was performed to estimate the effects of each included study on the overall risk of clinical outcomes. ORs and 95% CIs were recalculated when any single study was excluded in turn. Begg's test[14] and Egger's test[15] were performed to estimate the publication bias.

**RESULTS**

**Characteristics of selected studies**

According to the literature search strategy, a total of 220 articles were included in the final analysis. The characteristics of selected studies are shown in Table 1.
possibly relevant studies were retrieved and 195 were excluded. The main reasons for exclusion were that the articles were reviews, in vitro studies, irrelevant to the theme of our research, or did not meet our inclusion criteria (Figure 1). Twenty-five case-control studies met the inclusion criteria[8-11,16-36]. Four of these studies[10,11,19,32] investigated the association between babA2 gene and clinical outcomes in several different countries. Considering that these data partially evaluated the geographic variation of the influence of babA2 gene status on the risk of Helicobacter pylori-related gastroduodenal diseases, data that came from different countries were treated as a separate study. Therefore, with respect to geographical location, 16 studies11,17,19,22-26,29,33-36 were concerned with Asian populations, and 2 studies10,16,18,20,21,27,28,30-32 analyzed western populations. One of the latter group, which involved a study from Sweden[19], was excluded because of insufficient data. Finally, a total of 38 independent studies with 4556 patients were included in this meta-analysis (Table 1).

**Association between babA2 gene and PUD**

There were 36 studies26,30,11,17,19,22-26,29,33-36 that investigated the distribution difference of babA2 genotypes between patients with PUD and gastritis and/or NUD, which consisted of 1859 cases and 1909 controls. The overall prevalence of babA2 gene was 73.96% (1375/1859) in PUD patients and 57.94% (1106/1909) in control subjects. Data from Oleastro et al.[9] (Japan, South Korea, Brazil population), Sheu et al.[26] and Lai et al.[30] showed that the prevalence of babA2 gene was 100% in both case and control groups, and the OR and standard error could not be estimated; thus, these studies were excluded. We found that the babA2 gene significantly increased the risk of PUD in a random-effects model, with a pooled OR of 2.069 (95%CI: 1.532-2.794, \( P < 0.001 \)), and moderate heterogeneity was observed (\( I^2 = 62.8, P < 0.001 \) ) (Figure 2).

To explore the source of heterogeneity, subgroup analysis was performed. PUD was classified into DU and GU. Among the total of 36 PUD-related studies, 10 studies were excluded. We found that the OR and standard error could not be estimated; eight[22,24,26,27,29,33-35] could be used to evaluate risk for DU and eight[22,24,26,27,29,33-35] for GU. For DU analysis, the overall prevalence of babA2 gene in DU and control subjects was 77.20% (813/1053) and 71.77% (811/1130), respectively. After removal of two studies with 100% prevalence of babA2 genotype[26,27], the pooled OR based on the random-effects model was 1.588 (95%CI: 1.141-2.209, \( P = 0.006 \)), and mild heterogeneity was observed (\( I^2 = 45.8, P = 0.021 \) ) (Figure 2). For GU analysis, the overall prevalence of babA2 genotype seemed to be lower in GU (73.73%, 174/236) than in controls (80.89%, 402/497). Two studies with 100% prevalence of babA2 genotype were also excluded because of statistical limitation[26,34]. No significant association was observed between babA2 genotype and GU in a fixed-effects model (OR = 0.755, 95%CI: 0.496-1.150, \( P = 0.191 \)), and there was no heterogeneity among the studies (\( I^2 = 0.9%, P = 0.845 \) ) (Figure 2).

When geographical location was considered, data from different countries were subdivided into Asian and western groups. For PUD, the overall prevalence of babA2 gene was 78.36% (822/1049) in Asian countries and 68.27% (553/810) in western countries. Furthermore, in western countries, the presence of babA2 substantially increased PUD risk, with a pooled OR of 2.739 (95%CI: 1.860-4.032, \( P < 0.001 \)), while in Asian countries, the babA2 genotype was only borderline associated with PUD (OR = 1.370, 95%CI: 0.941-1.994, \( P = 0.100 \)) (Figure 2). For DU, the babA2 genotype significantly increased the risk of DU in western countries (OR = 2.239, 95%CI: 1.468-3.415, \( P < 0.001 \)), but not in Asian countries (OR = 1.158, 95%CI: 0.802-1.672, \( P = 0.433 \)) (Figure 2). The results suggested that differences in geographical distribution of babA2 genotype may also confer heterogeneity to the studies. Only one study with a small sample size investigated the relationship of babA2 gene and GU in a western country[27]; therefore, we did not perform subgroup analysis according to geographical area.

Sensitivity analysis was conducted to assess the influence of individual studies on the overall risk of PUD and DU by excluding any single study in turn and recalculating the pooled OR and 95%CI. A similar OR and 95%CI were generated, which indicated high stability of the results (Figure 3).

**Association between babA2 and GC**

A total of 16 studies10,11,16,17,22,24,26,29,30,31-36 investigated the association between babA2 gene and GC. The overall prevalence of babA2 gene was 70.72% (384/534) in GC cases and 60.64% (607/1001) in gastritis or NUD controls. One study with both 100% prevalence of babA2 in cases and controls was excluded from our meta-analysis[34]. In a random-effects model, the risk of GC increased 1.972-fold (95%CI: 1.103-3.525, \( P = 0.022 \) ) in the pres-
ence of \textit{bab}A2 compared with the controls; however, high heterogeneity among studies was observed ($I^2 = 76.8\%$, $P < 0.001$). Meta-analyses were conducted repeatedly when each study was omitted. As showed in Figure 4, two studies\cite{19,30} showed larger differences in the risk estimates compared with other studies in the sensitivity analysis. Sensitivity analysis excluding these studies generated an OR of 1.303 (95\%CI: 0.881-1.927, $P = 0.185$) among homogeneous studies ($I^2 = 45.0\%$, $P = 0.040$), which was different from the OR of 1.972 (95\%CI: 1.103-3.525, $P = 0.022$) before the removal of those studies (Figure 4). In terms of geographical area, no statistically significant findings were found among the Asian or western subpopulations, with a pooled OR of 1.132 (95\%CI: 0.763-1.680, $P = 0.539$) in the former and 1.303 (95\%CI: 0.881-1.927, $P = 0.349$) in the latter (Figure 4).

**DISCUSSION**

The Gram-negative bacterium \textit{H. pylori} is known to have a remarkably high level of genetic diversity, and is implicated in human diseases after decades of persistence in the stomach.\cite{8,17,19} A crucial virulence factor BabA, encoded by the \textit{bab}A2 gene, facilitates colonization by \textit{H. pylori} in the stomach and may be involved in the pathogenesis of different \textit{H. pylori}-related gastroduodenal diseases, such as PUD and gastric malignancy.\cite{8} To date, there have been numerous relevant studies published but with divergent results on the relationship between the \textit{bab}A2 gene and PUD and GC.\cite{8,11} Moreover, there is no comprehensive meta-analysis on the significance

| Ref. | Population | Gastritis or NUD | PUD | GU | DU | GC |
|------|------------|------------------|-----|----|----|----|
|      |            | babA2+ | babA2+ | babA2+ | babA2+ | babA2+ |
| Asian | Saxena et al\cite{9} | India | 35 (26.32) | 19 (52.78) | 10 (28.57) |
|       | Talebi Bezmim Abadi et al\cite{25} | Iran | 17 (26.15) | 10 (18.18) | 10 (18.18) | 38 (95.00) |
|       | Safavi et al\cite{27} | Iran | 30 (68.18) | 20 (74.07) | 20 (74.07) | 8 (80.00) |
|       | Oleastro et al\cite{31} | Japan | 28 (100.00) | 42 (100.00) | |
|       | Oleastro et al\cite{31} | South Korea | 37 (100.00) | 28 (100.00) | |
|       | Choonvarin et al\cite{40} | Thai | 57 (91.94) | 31 (91.18) | 17 (85.00) | 14 (100.00) | 15 (93.75) |
|       | Erzin et al\cite{23} | Turkey | 7 (23.33) | 14 (46.67) | 14 (46.67) | 29 (87.88) |
|       | Zhang et al\cite{32} | China | 89 (66.92) | 89 (60.14) | 28 (59.57) | 61 (60.40) | 54 (68.35) |
|       | Sheu et al\cite{34} | Taiwan | 85 (100.00) | 60 (100.00) | 30 (100.00) | 30 (100.00) |
|       | Zheng et al\cite{24} | China | 11 (37.93) | 17 (39.53) | |
|       | Han et al\cite{43} | China | 28 (65.12) | 50 (64.94) | 15 (50.00) | 35 (74.47) | 12 (57.14) |
|       | Lai et al\cite{40} | Taiwan | 41 (100.00) | 46 (100.00) | 15 (100.00) | 31 (100.00) | 14 (100.00) |
|       | Maeda et al\cite{17} | Japan | 52 (96.30) | 40 (95.24) | 20 (100.00) | 20 (90.91) | 11 (100.00) |
|       | Yamaoka et al\cite{32} | Korea | 47 (88.68) | 111 (96.52) | 111 (96.52) | |
|       | Yamaoka et al\cite{32} | Japan | 112 (88.89) | 172 (95.56) | 112 (88.89) | |
|       | Mizushima et al\cite{35} | Japan | 34 (80.95) | 73 (84.88) | 38 (84.44) | 35 (85.37) | 36 (90.00) |
| Western | Mattar et al\cite{11} | Brazil | 22 (64.71) | 14 (41.18) | |
|       | Oleastro et al\cite{31} | Portugal | 7 (11.67) | 27 (47.37) | |
|       | Bartchewsky et al\cite{10} | Brazil | 102 (79.07) | 40 (78.43) | |
|       | Oleastro et al\cite{31} | Portugal | 16 (32.00) | 25 (50.00) | |
|       | Oleastro et al\cite{31} | France | 3 (50.00) | 22 (81.48) | |
|       | Oleastro et al\cite{31} | Sweden | 4 (40.00) | 10 (83.33) | |
|       | Oleastro et al\cite{31} | Germany | 6 (60.00) | 7 (77.78) | |
|       | Oleastro et al\cite{31} | United States | 12 (92.31) | 10 (100.00) | |
|       | Oleastro et al\cite{31} | Brazil | 12 (100.00) | 10 (100.00) | |
|       | Oleastro et al\cite{31} | Portugal | 18 (32.14) | 25 (50.00) | |
|       | Gatti et al\cite{19} | Brazil | 16 (43.24) | 20 (40.00) | 11 (37.93) | 9 (42.86) |
|       | Gatti et al\cite{19} | Brazil | 37 (54.41) | 3 (20.00) | |
|       | Oflat et al\cite{32} | Finland | 12 (46.35) | 22 (70.97) | |
|       | Oflat et al\cite{32} | Portugal | 12 (19.67) | 19 (63.33) | |
|       | Oflat et al\cite{32} | Germany | 19 (28.36) | 22 (88.00) | |
|       | Oliveira et al\cite{36} | Brazil | 24 (31.58) | 43 (53.75) | 43 (53.75) | 29 (55.77) |
|       | Zambon et al\cite{28} | Italy | 26 (27.96) | 20 (48.78) | |
|       | Yamaoka et al\cite{32} | Colombia | 28 (70.00) | 34 (85.00) | 34 (85.00) | 34 (82.93) |
|       | Yamaoka et al\cite{32} | United States | 28 (70.00) | 35 (85.57) | 35 (85.57) | 19 (63.33) |
|       | Yamaoka et al\cite{32} | United States | 66 (71.74) | 123 (84.83) | 123 (84.83) | |
|       | Yamaoka et al\cite{32} | Colombia | 37 (71.15) | 53 (82.81) | 53 (82.81) | |
|       | Gerhard et al\cite{19} | Munich | 13 (37.14) | 23 (100.00) | 23 (100.00) | 21 (77.78) |

NUD: Nonulcer disease; PUD: Peptic ulcer disease; GU: Gastric ulcer; DU: Duodenal ulcer; GC: Gastric cancer.

**Publication bias analysis**

Publication bias was preliminarily estimated by Begg’s and Egger’s tests. No significant publication bias was observed in all the comparisons based on Begg’s test (all $P > 0.1$), but $P$ value was 0.08 in Egger’s test, suggesting a slight publication bias.
### A

**Ref.** | **Country** | **PUD babA2+/-** | **NUD/GS babA2+/-** | **OR (95%CI)** | **%Weight |
---|---|---|---|---|---|
**Asian**
Mizushima et al. [30] | Japan | 73/13 | 34/8 | 1.32 (0.50, 3.49) | 3.61 |
Maeda et al. [29] | Japan | 40/2 | 52/2 | 0.77 (0.10, 5.70) | 1.62 |
Yamaoka et al. [31] | South Korea | 111/4 | 47/6 | 3.54 (0.96, 13.13) | 2.75 |
Han et al. [32] | China | 50/27 | 28/15 | 0.99 (0.45, 2.17) | 4.15 |
Zheng et al. [33] | China | 17/26 | 11/18 | 1.07 (0.41, 2.82) | 3.61 |
Chomvarin et al. [34] | Thailand | 31/3 | 57/5 | 0.91 (2.0, 4.05) | 2.37 |
Erzin et al. [35] | Turkey | 14/16 | 7/23 | 2.88 (0.95, 8.72) | 3.23 |
Safaei et al. [36] | Iran | 20/7 | 30/14 | 1.33 (0.46, 3.88) | 3.34 |
Saxena et al. [37] | India | 19/17 | 35/98 | 3.13 (1.46, 6.99) | 4.22 |
Talebi Bezmin Abadi et al. [38] | Iran | 10/45 | 17/48 | 0.63 (0.26, 1.51) | 3.86 |
**Subtotal (I² = 46.3%, P = 0.039)** | | | | 1.37 (0.94, 1.99) | 41.58 |

**Western**
Gerhardt et al. [39] | Munich | 23/0 | 13/22 | 78.33 (4.39, 1397.21) | 0.92 |
Yamaoka et al. [31] | Colombia | 34/6 | 28/12 | 2.43 (0.81, 7.30) | 3.26 |
Yamaoka et al. [31] | United States | 35/6 | 28/12 | 2.30 (0.83, 7.50) | 2.36 |
Yamaoka et al. [31] | United States | 123/22 | 66/26 | 2.20 (1.16, 4.18) | 4.57 |
Yamaoka et al. [31] | Colombia | 53/11 | 37/15 | 1.95 (0.81, 4.73) | 3.85 |
Oliveira et al. [31] | Brazil | 43/37 | 24/52 | 2.52 (1.31, 4.84) | 4.45 |
Zambon et al. [40] | Italy | 20/21 | 26/67 | 2.45 (1.15, 5.26) | 4.21 |
Gatti et al. [41] | Brazil | 3/12 | 37/31 | 0.21 (0.05, 0.81) | 2.66 |
Olfat et al. [42] | Finland | 22/9 | 12/14 | 2.85 (0.96, 8.51) | 3.27 |
Olfat et al. [42] | Portugal | 19/11 | 12/49 | 7.05 (2.66, 18.69) | 3.59 |
Olfat et al. [42] | Germany | 22/3 | 19/48 | 18.53 (4.96, 69.22) | 2.74 |
Gatti et al. [41] | Brazil | 20/30 | 16/21 | 0.88 (0.37, 2.07) | 3.92 |
Oleastro et al. [43] | Portugal | 25/25 | 18/38 | 2.11 (0.96, 4.46) | 4.13 |
Oleastro et al. [43] | Portugal | 25/25 | 16/34 | 2.13 (0.94, 4.79) | 4.06 |
Oleastro et al. [43] | France | 22/5 | 3/3 | 4.40 (0.68, 28.60) | 1.78 |
Oleastro et al. [43] | Sweden | 10/2 | 4/6 | 7.50 (1.04, 54.12) | 1.65 |
Oleastro et al. [43] | Germany | 7/2 | 6/4 | 2.33 (0.31, 17.54) | 1.60 |
Oleastro et al. [43] | United States | 10/0 | 12/1 | 2.52 (0.59, 68.00) | 0.72 |
Oleastro et al. [43] | Portugal | 27/30 | 7/53 | 2.74 (1.86, 4.03) | 58.42 |
**Subtotal (I² = 59.1%, P = 0.001)** | | | | 2.07 (1.53, 2.79) | 100.00 |
**Overall (I² = 62.8%, P = 0.000)** | | | | 2.07 (1.53, 2.79) | 100.00 |

**Note:** Weights are from random effects analysis

### B

**Ref.** | **Country** | **DU babA2+/-** | **NUD/GS babA2+/-** | **OR (95%CI)** | **%Weight |
---|---|---|---|---|---|
**Asian**
Mizushima et al. [30] | Japan | 35/6 | 34/8 | 1.37 (0.43, 4.37) | 5.18 |
Maeda et al. [29] | Japan | 20/2 | 52/2 | 0.38 (0.05, 2.92) | 2.24 |
Yamaoka et al. [31] | South Korea | 111/4 | 47/6 | 3.54 (0.96, 13.13) | 4.40 |
Yamaoka et al. [31] | Japan | 112/4 | 112/14 | 1.00 (0.46, 2.19) | 7.92 |
Han et al. [32] | China | 35/12 | 28/15 | 1.56 (0.63, 3.87) | 6.89 |
Chomvarin et al. [34] | Thailand | 14/0 | 57/5 | 2.77 (0.14, 53.09) | 1.15 |
Erzin et al. [35] | Turkey | 14/16 | 7/23 | 2.88 (0.95, 8.72) | 5.48 |
Safaei et al. [36] | Iran | 61/40 | 89/44 | 0.75 (0.44, 1.29) | 10.40 |
Talebi Bezmin Abadi et al. [38] | Iran | 20/7 | 30/14 | 1.33 (0.46, 3.88) | 5.73 |
**Subtotal (I² = 23.1%, P = 0.231)** | | | | 1.16 (0.80, 1.67) | 56.49 |

**Western**
Gerhardt et al. [39] | Munich | 23/0 | 13/22 | 78.33 (4.39, 1397.21) | 1.20 |
Yamaoka et al. [31] | Colombia | 34/6 | 28/12 | 2.43 (0.81, 7.30) | 5.53 |
Yamaoka et al. [31] | United States | 35/6 | 28/12 | 2.50 (0.83, 7.50) | 5.54 |
Yamaoka et al. [31] | United States | 123/22 | 66/26 | 2.20 (1.16, 4.18) | 9.31 |
Yamaoka et al. [31] | Colombia | 53/11 | 37/15 | 1.95 (0.81, 4.73) | 7.07 |
Oliveira et al. [31] | Brazil | 43/37 | 24/52 | 2.52 (1.31, 4.84) | 9.19 |
Gatti et al. [41] | Brazil | 9/12 | 16/21 | 0.98 (0.33, 2.90) | 5.65 |
**Subtotal (I² = 28.1%, P = 0.214)** | | | | 2.24 (1.47, 3.42) | 43.51 |
**Overall (I² = 45.8%, P = 0.021)** | | | | 1.59 (1.14, 2.21) | 100.00 |

**Note:** Weights are from random effects analysis

*Ref.:* BabA2, babA2, PUD, NUD, GS.

*Note:* Weights are from random effects analysis.
of \textit{babA2}. Therefore, we performed the present meta-analysis of the available published literature to obtain a more precise conclusion. Our meta-analysis showed that \textit{babA2} was significantly associated with increased risks of PUD, especially DU, with corresponding ORs of 2.069 and 1.588; moreover, statistically significant findings were more apparent in western populations with ORs of 2.739 for PUD and 2.239 for DU. The summary ORs for PUD and DU in Asians, however, were relatively small (1.370 and 1.158, respectively) and without statistical significance. No significant risk association was observed for GU and GC, but a decreased tendency was noted for GU with a pooled OR of 0.755.

Over the past 20 years, there has been marked progress in our understanding of the role of \textit{H. pylori} infection in the etiology of gastroduodenal diseases. It is well known that \textit{H. pylori} infection increases the risk of developing PUD, including both GU and DU subtypes\cite{30-32}. Our meta-analysis confirmed a positive association of \textit{H. pylori} with \textit{babA2} genotype with PUD development. Among the major outer membrane proteins of \textit{H. pylori}, BabA has significance not only in triggering bacterial colonization of the gastric epithelium, but also in regulating its functional interaction with host cells, which mainly acts through binding to Lewis\textsuperscript{b} and fucosylated ABO blood group antigens present in the stomach\cite{33,34}. Gene inactivation experiments have demonstrated that only the product of \textit{babA2} gene is essential for Lewis\textsuperscript{b} binding activity\cite{35}. Rad et al\cite{36} have reported a high density of \textit{H. pylori} colonization in the stomach in the presence of \textit{babA2} genotype, which increases interleukin-8 secretion and granulocytic infiltration, resulting in intense mucosal inflammation. In addition, Ishijima et al\cite{37} have demonstrated that \textit{babA2}-positive strains with Lewis\textsuperscript{b} binding activity are potentiators of the type IV secretion system (T4SS), implying a possible combined effect of \textit{babA2} and other virulence factors related to T4SS. Although the detailed mechanism of the pathogenicity of \textit{babA2} in PUD development has not been fully established, our meta-analysis suggests an important role of \textit{babA2} genotype in distinguishing \textit{H. pylori}-related PU and especially DU from NUD.

Intriguing findings in this study further suggested that individuals infected with \textit{babA2}-positive pathogens have a unique pathogenicity in DU development; conversely, there was no significant association between \textit{babA2} and GC. This difference may be partially due to the distinct etiologies of DU and GC development. Generally, \textit{H. pylori}-related chronic severe gastritis could progress in two different directions\cite{44}. One possibility is that \textit{H. pylori}-related gastritis, predominating in the antrum as well as generating gastric acid, usually induces DU\cite{45}. Patients with DU rarely develop atrophic gastritis of the corpus, and therefore GC risk may decrease in such cases\cite{46}. Another possibility is that patients with extensive gastritis in the corpus and antrum, involving decreased acid output, tend to develop intestinal metaplasia, atrophic gastritis, and even GC\cite{47}. It is speculated that \textit{babA2} combined with other virulence factors may also lead to GC development. Studies conducted by Gerhard et al\cite{48} and Erizin et al\cite{49} have suggested that triple-positive \textit{H. pylori} strains with \textit{cagA}, \textit{vacAs1} and \textit{babA2} coexpression increase the risk of developing GC. Zambon et al\cite{50} have also reported that infections with these triple-positive strains carry a higher risk of intestinal metaplasia, known as a gastric precancerous lesion. The different risk associations between GC and DU should be interpreted with caution, which should be further investigated in the future.

Our stratified analysis according to geographical areas demonstrated that \textit{babA2} genotype is closely involved in the risk of PUD, especially DU in western populations, but not in Asian populations. This important information about geographical difference in the \textit{babA2} gene suggests a potential biomarker distinguishing PUD, especially DU, from other NUDs in western populations, and reveals a phylogenetic difference between Asian and western \textit{H. pylori} strains. Previous studies have also reported divergence in genes accounting for BabA and other virulence genes, such as \textit{cagA} and \textit{vacA}, between Asian and western strains\cite{48-50}. The above-mentioned findings support the

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Results of the association between \textit{babA2} gene and peptic ulcer disease, duodenal ulcer and gastric ulcer risk. A: Association between \textit{babA2} and peptic ulcer disease (PUD); B: Association between \textit{babA2} and duodenal ulcer (DU); C: Association between \textit{babA2} and gastric ulcer (GU). ORs and 95% CIs were calculated by a random-effect (A, B) and fixed-effect (C) model. NUD: Nonulcer disease.}
\end{figure}
suggestion that genetic variability within the *H. pylori* genome, especially in probable host interaction genes, plays a critical role in its different adaptive ability and pathogenicity among different ethnicities.

There were several unavoidable limitations to our meta-analysis that should be considered. First, 17 studies related to PUD lacked information about the distribution of DU and GU, which may have influenced the results of the stratified analysis. Second, a lack of original data on histopathological types of GC limited the subgroup analysis according to differences in these types. An unstable result was obtained according to the sensitivity analysis that assessed the relationship between *babA2* and GC, but there were insufficient data to explore

---

**Figure 3** Influence of the summary OR coefficients on the association between *babA2* genotype and peptic ulcer disease and duodenal ulcer risk. A: *babA2* genotype and peptic ulcer disease (PUD) risk; B: *babA2* genotype and duodenal ulcer risk. Results were calculated by omitting each study (on the left) in turn. Bars, 95% CI. Meta-analysis random-effects estimates (exponential form) were used.
In conclusion, our results suggest that the presence of \textit{babA2} may contribute to increased risk of PUD, especially DU development, in western countries. In Asians, \textit{babA2} genotype only showed a marginal association with PUD risk, which requires further investigation in the future.

**COMMENTS**

**Background**

\textit{Helicobacter pylori} (\textit{H. pylori}) is a common bacterium with a high prevalence rate and severe pathogenicity, which has been identified as a major cause of severe gastroduodenal diseases, such as peptic ulcer disease (PUD) and gastric cancer (GC). The genome of various \textit{H. pylori} strains demonstrates significant genetic diversity. Genetic variation in specific virulence genes of \textit{H. pylori} may participate in the pathogenic process of \textit{H. pylori} infection in the stomach, thereby contributing to the variable risk of diverse clinical outcomes.

**Research Frontiers**

BabA encoded by the \textit{babA2} gene is a crucial virulence factor of \textit{H. pylori}, which may be involved in the pathogenesis of PUD and GC. Although a few studies have focused on the association between \textit{babA2} gene and the risks of \textit{H. pylori}-related gastroduodenal diseases, those studies showed discrepant results. Moreover, there is no comprehensive meta-analysis integrating the currently available data on the relationship between \textit{babA2} gene and PUD and GC.

**Innovations and Breakthroughs**

This meta-analysis investigated the association between \textit{babA2} gene and PUD and GC. They observed that the presence of \textit{babA2} may contribute to increased risk of PUD, especially duodenal ulcer (DU) development, in western countries. However, in Asians, the presence of \textit{babA2} only showed a marginal association with PUD risk, which requires further investigation. This meta-analysis achieved a relatively comprehensive conclusion on the relationship between \textit{babA2} and clinical outcomes.

**Applications**

The study suggested that individuals infected with \textit{H. pylori} harboring \textit{babA2} gene were associated with increased risk of PUD, especially DU, in western countries. Eradication of \textit{H. pylori}, in particular \textit{H. pylori} harbouring \textit{babA2}, may contribute to a lower incidence of PUD.
REFERENCES

1 Suzuki R, Shiotai S, Yamaoka Y. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infect Genet Evol 2012; 12: 203-213 [PMID: 22197766 DOI: 10.1016/j.meegid.2011.12.002]

2 Wroblewski LE, Peer RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 23: 713-739 [PMID: 20930071 DOI: 10.1128/CMR.00011-10]

3 Dhar SK, Soni RK, Das BK, Mukhopadhyay G. Molecular mechanism of action of major Helicobacter pylori virulence factors. Mol Cell Biochem 2003; 253: 207-215 [PMID: 14619971 DOI: 10.1023/A:]

4 Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 2010; 7: 629-641 [PMID: 20938460]

5 Sheu BS, Yang HB, Yeh YC, Wu JI. Helicobacter pylori colonization of the human gastric epithelium: a bug’s first step is a novel target for us. J Gastroenterol Hepatol 2010; 25: 26-32 [PMID: 20136973 DOI: 10.1111/j.1440-1746.2009.06141.x]

6 Yamaoka Y. Roles of Helicobacter pylori BabA in gastrointestinal pathogenesis. World J Gastroenterol 2008; 14: 4265-4272 [PMID: 18666312 DOI: 10.3748/wjg.14.4265]

7 Ilver D, Arnqvist A, Olfat FO, Módena JL, de Oliveira RB, Brocchi M. Prevalence of Helicobacter pylori SabA enhances H. pylori density in patients lacking interleukin 1 receptor antagonist gene and PUD and GC, and concluded that the presence of babA2 may be associated with increased risk of PUD, with an emphasis on DU and in western countries. This study was well designed and performed, and the results are well discussed.

8 Wu JJ. Interaction between host gastric sialyl-Lewis X and H. pylori. J Clin Microbiol 2010; 48: 2885-2891 [PMID: 20554820 DOI: 10.1128/JCM.00401-10]

9 Talebi Bezmin Abadi A, Taghvaei T, Mohabbati Moezab A, Vaira D, Vaira G, Vaira D. High correlation of babA (2)-positive strains of Helicobacter pylori with the presence of gastric cancer. World J Gastroenterol 2009; 15: 2073-2080 [PMID: 19245202 DOI: 10.3748/wjg.15.2073]

10 Erzin Y, Koskela V, Altun S, Dobrucali A, Aslan M, Erdamar S, Goksel S, Dinican A, Kocazeybek B. Role of host interleukin 1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in Helicobacter pylori-positive Turkish patients with dyspepsia. J Gastroenterol 2008; 43: 705-710 [PMID: 18807132 DOI: 10.1007/s00535-008-2220-7]

11 Chen MY,gets, and gastric cancer: factors that modulate disease risk. Gut Pathog 2010; 5: 1 [PMID: 20205796 DOI: 10.1186/1471-230X-8-49]

12 Zeng PY, Tang FA, Qi YM, Li J. Association of peptic ulcer with increased expression of Lewis antigens, but not vacuolating cytotoxin activity or babA2 gene status, in Helicobacter pylori strains from China. Chin J Dig Dis 2006; 7: 61-65 [PMID: 16412040 DOI: 10.1111/j.1443-9573.2006.00246.x]

13 Sheu BS, Olenbrecht S, Hung KH, Liu CP, Sheu SM, Yang HB, Wu JF. Interaction between host gastric Sialyl-Lewis X and H. pylori SabA enhances H. pylori density in patients lacking gastric Lewis B antigen. Am J Gastroenterol 2006; 101: 36-44 [PMID: 16405531 DOI: 10.1111/j.1572-0241.2006.00358.x]

14 Gatti LL, Módena JL, Payão SL, Smith Mde A, Fukuhara Y, Módena JL, de Oliveira RB, Brochmi M. Prevalence of Helicobacter pylori cagA, icaA and babA2 alleles in Brazilian patients with upper gastrointestinal diseases. Acta Trop 2006; 100: 252-240 [PMID: 17181989 DOI: 10.1016/j.actatropica.2006.08.014]

15 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 100-1101 [PMID: 7798690 DOI: 10.2207/253346]

16 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634 [PMID: 9310855 DOI: 10.1136/bmj.315.7109.629]

17 Matar R, Monteiro MS, Marques SB, Zilberstein B, Hashimoto CL, Carrilho FJ. Association of LEC and InPA Helicobacter pylori genes with gastric cancer in a Brazilian population. Infect Agent Cancer 2010; 5: 1 [PMID: 20205796 DOI: 10.1186/1471-230X-8-49]
Chen MY et al. babA2 genotype and gastroduodenal diseases

28 Gatti LL, Fagundes e Souza WK, Leite KR, Bastos EL, Vicentini LR, Silva LC, Smith Mde A, Payão SL. cagA vacA alleles and babA2 genotypes of Helicobacter pylori associated with gastric disease in Brazilian adult patients. *Diagn Microbiol Infect Dis* 2005; 51: 231-235 [PMID: 15808513 DOI: 10.1016/j.diagmicrobio.2004.11.007]

29 Han YH, Liu WZ, Zhu HY, Xiao SD. Clinical relevance of iceA and babA2 genotypes of Helicobacter pylori in a Shanghai population. *Chin J Dig Dis* 2004; 5: 181-185 [PMID: 15612889 DOI: 10.1111/j.1443-9573.2004.00175.x]

30 Zambon CF, Navaglia F, Basso D, Rugge M, Plebani M. Helicobacter pylori babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. *J Clin Pathol* 2003; 56: 287-291 [PMID: 12665641 DOI: 10.1136/jcp.56.4.287]

31 Oliveira AG, Santos A, Guerra JB, Rocha GA, Rocha AM, Oliveira CA, Cabral MM, Nogueira AM, Queiroz DM. babA2- and cagA-positive Helicobacter pylori strains are associated with duodenal ulcer and gastric carcinoma in Brazil. *J Clin Microbiol* 2003; 41: 3964-3966 [PMID: 12904430 DOI: 10.1128/JCM.41.8.3964-3966.2000]

32 Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutiérrez O, Osato MS, Graham DY. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. *Gastroenterology* 2002; 123: 414-424 [PMID: 12145793 DOI: 10.1053/gast.2002.34781]

33 Maeda S, Amarsanaa J, Mitsuyo H, Hirata Y, Akunama M, Ikenoue T, Ogura K, Yoshida H, Shiratori Y, Omata M. Relationship between nuclear factor-kappaB activation and virulence factors of Helicobacter pylori in Japanese clinical isolates. *J Gastroenterol Hepatol* 2002; 17: 556-562 [PMID: 12084029 DOI: 10.1046/j.1440-1746.2002.02738.x]

34 Lai CH, Kuo CH, Chen YC, Chao FY, Poon SK, Chang CS, Wang WC. High prevalence of cagA- and babA2-positive Helicobacter pylori clinical isolates in Taiwan. *J Clin Microbiol* 2002; 40: 3860-3862 [PMID: 12354901 DOI: 10.1128/JCM.40.10.3860-3862.2002]

35 Mizushima T, Sugiyama T, Komatsu Y, Ishizuka J, Kato M, Asaka M. Clinical relevance of the babA2 genotype of Helicobacter pylori in Japanese clinical isolates. *J Clin Microbiol* 2001; 39: 2463-2465 [PMID: 11427555 DOI: 10.1128/JCM.39.7.2463-2465.2001]

36 Saxena A, Shukla S, Prasad KN, Ghoshal UC. Virulence attributes of Helicobacter pylori isolates & their association with gastroduodenal disease. *Indian J Med Res* 2011; 133: 514-520 [PMID: 21623037]

37 Hovey JW, Watson EL, Langford ML, Hildebrandt E, Bathala S, Bolland JR, Spadafora D, Mendz GL, McGee DJ. Genetic microheterogeneity and phenotypic variation of Helicobacter pylori arginase in clinical isolates. *BMC Microbiol* 2007; 7: 26 [PMID: 17408487 DOI: 10.1186/1471-2180-7-26]

38 Guo C, Cao Y, Li Y, Liu D, Guo J, Guo Y, Wu Y, Cui Y, Sun H, Zhang J, Chen B, Zou Q, Guo G. Genotyping analysis of Helicobacter pylori using multiple-locus variable-number tandem-repeats analysis in five regions of China and Japan. *BMC Microbiol* 2011; 11: 197 [PMID: 21888662 DOI: 10.1186/1471-2180-11-197]

39 Maeda S, Mentsis AF. Pathogenesis of Helicobacter pylori infection. *Helicobacter* 2007; 12 Suppl 1: 10-14 [PMID: 17727454 DOI: 10.1111/j.1521-5378.2007.00529.x]

40 Schöttler B, Adanu MA, Weck MN, Brenner H. Helicobacter pylori infection is strongly associated with gastric and duodenal ulcers in a large prospective study. *Clin Gastroenterol Hepatol* 2012; 10: 487-493.e1 [PMID: 22230167]

41 Ishijima N, Suzuki M, Ashida H, Ichikawa Y, Kanegae Y, Saito I, Boren T, Haas R, Sasakawa C, Mimuro H. BabA-mediated adherence is a potentiator of the Helicobacter pylori type IV secretion system activity. *J Biol Chem* 2011; 286: 25256-25264 [PMID: 21596743 DOI: 10.1074/jbc.M111.233601]

42 Styer CM, Hansen LM, Cooke CL, Gunderson AM, Choi SS, Berg DE, Benghezal M, Marshall BJ, Peek RM, Boren T, Solnick JV. Expression of the BabA adhesin during experimental infection with Helicobacter pylori. *Infect Immun* 2010; 78: 1593-1600 [PMID: 20123715 DOI: 10.1128/IAI.01297-09]

43 Rad R, Gerhard M, Lang R, Schöngger, Rösch T, Schepp W, Becker I, Wagner H, Prinz C. The Helicobacter pylori blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response. *J Immunol* 2002; 168: 3033-3041 [PMID: 11884476]

44 Egan BJ, Holmes K, O’Connor HJ, O’Morain CA. Helicobacter pylori gastritis, the unifying concept for gastric diseases. *Helicobacter* 2007; 12 Suppl 2: 39-44 [PMID: 17991175 DOI: 10.1111/j.1523-5378.2007.00575.x]

45 Tan VP, Wong BC. Helicobacter pylori and gastritis: Untangling a complex relationship 27 years on. *Gastroenterol Hepatol* 2011; 26 Suppl 1: 42-45 [PMID: 21199513 DOI: 10.1111/j.1440-1746.2010.08593.x]

46 Ubukata H, Nagata H, Tabuchi T, Konishi S, Kasuga T, Tabuchi T. Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer. *Gastric Cancer* 2011; 14: 4-12 [PMID: 21249411 DOI: 10.1007/s10120-011-0005-9]

47 Erzin Y, Koksal V, Altun S, Dobrucali A, Aslan M, Erdamar S, Dirican A, Kocazeybek B. Prevalence of Helicobacter pylori vacA, cagA, cagE, iceA, babA2 genotypes and correlation with clinical outcome in Turkish patients with dyspepsia. *Helicobacter* 2006; 11: 574-580 [PMID: 17083380 DOI: 10.1111/j.1523-5378.2006.00461.x]

48 Pride DT, Meinersmann RJ, Blaser MJ. Allelic Variation within Helicobacter pylori babA and babB. *Infect Immun* 2001; 69: 1160-1171 [PMID: 11160014 DOI: 10.1128/IAI.69.2.1160-1171.2001]

49 Kawai M, Furuta Y, Yahara K, Tsuru T, Oshima K, Handa N, Takahashi N, Yoshida M, Azuma T, Hattori M, Uchiyama I, Takahashi N, Hattori M, Uchiyama I. Evolution in an oncogenic bacterial species with extreme genome plasticity: Helicobacter pylori East Asian genomes. *BMC Microbiol* 2011; 11: 104 [PMID: 21575176 DOI: 10.1186/1471-2180-11-104]

50 Ghose C, Perez-Perez GI, Dominguez-Bello MG, Pride DT, Bravi CM, Blaser MJ. East Asian genotypes of Helicobacter pylori strains in Amerindians provide evidence for its ancient human carriage. *Proc Natl Acad Sci USA* 2002; 99: 15107-15111 [PMID: 12417749 DOI: 10.1073/pnas.242574599]
